CA2340999C - 5-arylindole derivatives - Google Patents

5-arylindole derivatives Download PDF

Info

Publication number
CA2340999C
CA2340999C CA002340999A CA2340999A CA2340999C CA 2340999 C CA2340999 C CA 2340999C CA 002340999 A CA002340999 A CA 002340999A CA 2340999 A CA2340999 A CA 2340999A CA 2340999 C CA2340999 C CA 2340999C
Authority
CA
Canada
Prior art keywords
compound
pharmaceutically acceptable
acceptable salt
salt according
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA002340999A
Other languages
English (en)
French (fr)
Other versions
CA2340999A1 (en
Inventor
John Eugene Macor
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Ltd Great Britain
Original Assignee
Pfizer Ltd Great Britain
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Ltd Great Britain filed Critical Pfizer Ltd Great Britain
Publication of CA2340999A1 publication Critical patent/CA2340999A1/en
Application granted granted Critical
Publication of CA2340999C publication Critical patent/CA2340999C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
CA002340999A 1992-11-02 1993-10-19 5-arylindole derivatives Expired - Fee Related CA2340999C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US97075892A 1992-11-02 1992-11-02
US07/970,758 1992-11-02
CA002148380A CA2148380C (en) 1992-11-02 1993-10-19 5-arylindole derivatives

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CA002148380A Division CA2148380C (en) 1992-11-02 1993-10-19 5-arylindole derivatives

Publications (2)

Publication Number Publication Date
CA2340999A1 CA2340999A1 (en) 1994-05-11
CA2340999C true CA2340999C (en) 2005-01-04

Family

ID=25517470

Family Applications (2)

Application Number Title Priority Date Filing Date
CA002340999A Expired - Fee Related CA2340999C (en) 1992-11-02 1993-10-19 5-arylindole derivatives
CA002148380A Expired - Fee Related CA2148380C (en) 1992-11-02 1993-10-19 5-arylindole derivatives

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA002148380A Expired - Fee Related CA2148380C (en) 1992-11-02 1993-10-19 5-arylindole derivatives

Country Status (27)

Country Link
US (1) US5886008A (oth)
EP (2) EP1094064A1 (oth)
JP (1) JP2788551B2 (oth)
KR (1) KR0163371B1 (oth)
CN (1) CN1051313C (oth)
AT (1) ATE202102T1 (oth)
AU (1) AU685066B2 (oth)
BR (1) BR9307348A (oth)
CA (2) CA2340999C (oth)
CZ (1) CZ283001B6 (oth)
DE (1) DE69330351T2 (oth)
DK (1) DK0666858T3 (oth)
EG (1) EG20396A (oth)
ES (1) ES2157224T3 (oth)
FI (2) FI111257B (oth)
GR (1) GR3036579T3 (oth)
HU (1) HU222235B1 (oth)
IL (1) IL107386A (oth)
MY (1) MY109696A (oth)
NO (1) NO309652B1 (oth)
NZ (1) NZ257059A (oth)
PL (1) PL176091B1 (oth)
PT (1) PT666858E (oth)
RU (1) RU2134266C1 (oth)
TW (1) TW251284B (oth)
WO (1) WO1994010171A1 (oth)
ZA (1) ZA938137B (oth)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9210400D0 (en) * 1992-05-15 1992-07-01 Merck Sharp & Dohme Therapeutic agents
DK0716649T3 (da) * 1993-08-31 1999-02-08 Pfizer 5-Arylindolderivater
JP2829788B2 (ja) * 1994-02-10 1998-12-02 ファイザー インク． ベンゾジアゼピン受容体部位アゴニスト及びアンタゴニストとしての５−ヘテロアリールインドール誘導体
GB9420529D0 (en) 1994-10-12 1994-11-30 Pfizer Ltd Indoles
NZ305166A (en) * 1995-03-20 1998-12-23 Lilly Co Eli 5-substituted-3-(1,2,3,6-tetrahydropyridin-4-yl)- and 3-(piperidin-4-yl)-1h-indoles; preparation and medicaments
US5942536A (en) * 1995-10-10 1999-08-24 Eli Lilly And Company N- 2-substituted-3-(2-aminoethyl)-1H-indol-5-YL!-Amides: new 5-HT1F agonists
PL337888A1 (en) 1997-07-03 2000-09-11 Du Pont Pharm Co Imidazoprimidines and imidazopyridines for use in treating neurological disorders
US6465484B1 (en) 1997-09-26 2002-10-15 Merck & Co., Inc. Angiogenesis inhibitors
US7189753B1 (en) 1997-11-06 2007-03-13 Cady Roger K Preemptive prophylaxis of migraine
EP1100501A4 (en) * 1998-06-30 2002-12-04 Lilly Co Eli PYRROLIDINE AND PYRROLIDINE DERIVATIVES INFLUENTING THE SYSTEMS ASSOCIATED WITH SEROTONIN
US6365589B1 (en) 1998-07-02 2002-04-02 Bristol-Myers Squibb Pharma Company Imidazo-pyridines, -pyridazines, and -triazines as corticotropin releasing factor antagonists
GB9819035D0 (en) * 1998-09-01 1998-10-28 Cerebrus Res Ltd Chemical compounds VII
US5994352A (en) * 1998-11-13 1999-11-30 Pfizer Inc. 5-arylindole derivatives
PE20030008A1 (es) 2001-06-19 2003-01-22 Bristol Myers Squibb Co Inhibidores duales de pde 7 y pde 4
US20040102360A1 (en) * 2002-10-30 2004-05-27 Barnett Stanley F. Combination therapy
JP2006507299A (ja) 2002-10-30 2006-03-02 メルク　エンド　カムパニー　インコーポレーテッド Ａｋｔ活性の阻害薬
US7332508B2 (en) 2002-12-18 2008-02-19 Novo Nordisk A/S Substituted homopiperidine, piperidine or pyrrolidine derivatives
EP1620095A4 (en) 2003-04-24 2009-04-01 Merck & Co Inc HEMMER OF ACT ACTIVITY
DE10337184A1 (de) 2003-08-13 2005-03-10 Gruenenthal Gmbh Substituierte 3-Pyrrolidin-Indol-Derivate
US7442709B2 (en) * 2003-08-21 2008-10-28 Osi Pharmaceuticals, Inc. N3-substituted imidazopyridine c-Kit inhibitors
DE602004020073D1 (de) * 2003-08-21 2009-04-30 Osi Pharm Inc 3-substituierte imidazopyridinderivate als c-kit-inhibitoren
CA2540541C (en) 2003-10-03 2012-03-27 3M Innovative Properties Company Alkoxy substituted imidazoquinolines
WO2005051317A2 (en) 2003-11-25 2005-06-09 3M Innovative Properties Company Substituted imidazo ring systems and methods
DE102004014304A1 (de) 2004-03-22 2005-10-06 Grünenthal GmbH Substituierte 1,4,8- Triazaspiro[4,5]decan-2-on-Verbindungen
WO2006084251A2 (en) 2005-02-04 2006-08-10 Coley Pharmaceutical Group, Inc. Aqueous gel formulations containing immune reponse modifiers
BRPI0709077A2 (pt) * 2006-03-22 2012-04-10 Janssen Pharmaceutica Nv derivados de alquilaminas cìclicas como inibidores da interação entre mdm2 e p53
US20140206667A1 (en) 2012-11-14 2014-07-24 Michela Gallagher Methods and compositions for treating schizophrenia
WO2014144663A1 (en) 2013-03-15 2014-09-18 The Johns Hopkins University Methods and compositions for improving cognitive function
AU2014228512A1 (en) 2013-03-15 2015-10-01 Agenebio, Inc. Methods and compositions for improving cognitive function
RS61688B1 (sr) * 2015-04-29 2021-05-31 Janssen Pharmaceutica Nv Azabenzimidazoli i njihiova upotreba kao modulatori ampa receptora
AU2016255424B2 (en) 2015-04-29 2020-10-08 Janssen Pharmaceutica Nv Benzimidazolone and benzothiazolone compounds and their use as AMPA receptor modulators
US10604484B2 (en) 2015-04-29 2020-03-31 Janssen Pharmaceutica Nv Indolone compounds and their use as AMPA receptor modulators
WO2016176457A1 (en) 2015-04-29 2016-11-03 Janssen Pharmaceutica Nv Imidazopyrazines and pyrazolopyrimidines and their use as ampa receptor modulators
CA2986598C (en) 2015-05-22 2023-09-26 Agenebio, Inc. Extended release pharmaceutical compositions of levetiracetam
CN108137561B (zh) 2015-11-06 2021-03-26 豪夫迈·罗氏有限公司 二氢吲哚-2-酮衍生物
EP3371169B1 (en) 2015-11-06 2019-07-17 H. Hoffnabb-La Roche Ag Indolin-2-one derivatives for use in the treatment of cns and related disorders
CN108137555B (zh) 2015-11-06 2021-02-19 豪夫迈·罗氏有限公司 可用于治疗cns疾病的二氢吲哚-2-酮衍生物
ES2808920T3 (es) 2015-11-06 2021-03-02 Hoffmann La Roche Derivados de indolin-2-ona
CN111822047B (zh) * 2020-07-17 2022-05-27 曲阜师范大学 一种磁性介孔聚合离子液体负载催化合成吲哚类衍生物的方法
WO2025104491A1 (en) * 2023-11-14 2025-05-22 Mindset Pharma Inc. Indole derivatives as serotonergic agents useful for the treatment of disorders related thereto
WO2025104490A1 (en) * 2023-11-14 2025-05-22 Mindset Pharma Inc. Indole derivatives as serotonergic agents useful for the treatment of disorders related thereto

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA795239B (en) * 1978-10-12 1980-11-26 Glaxo Group Ltd Heterocyclic compounds
ZA815541B (en) * 1980-08-12 1983-03-30 Glaxo Group Ltd Heterocyclic compounds
US4983622A (en) * 1984-02-06 1991-01-08 Eli Lilly And Company 6-substituted-4-dialkylaminotetrahydrobenz(c,d)indoles
GB8600397D0 (en) * 1986-01-08 1986-02-12 Glaxo Group Ltd Chemical compounds
GB8719167D0 (en) * 1987-08-13 1987-09-23 Glaxo Group Ltd Chemical compounds
GB8724912D0 (en) * 1987-10-23 1987-11-25 Wellcome Found Indole derivatives
GB8819024D0 (en) * 1988-08-10 1988-09-14 Glaxo Group Ltd Chemical compounds
IL96891A0 (en) * 1990-01-17 1992-03-29 Merck Sharp & Dohme Indole-substituted five-membered heteroaromatic compounds,their preparation and pharmaceutical compositions containing them
US5340838A (en) * 1990-05-04 1994-08-23 Eli Lilly And Company Method of inhibiting gastric acid secretion with 2-phenylcyclopropylamines
CA2042295A1 (fr) * 1990-05-15 1991-11-16 Jacques Chauveau Derives de mediateurs endogenes, leurs sels, procede de preparation, applications, et compositions les renfermant
PT97888B (pt) * 1990-06-07 1998-12-31 Zeneca Ltd Processo para a preparacao de compostos heterociclicos derivados de indol e de composicoes farmaceuticas que os contem
DK158590D0 (da) * 1990-07-02 1990-07-02 Lundbeck & Co As H Indolderivater
PL170330B1 (pl) * 1990-10-15 1996-11-29 Pfizer Sposób wytwarzania nowych pochodnych indolu PL PL PL PL PL PL
SK278998B6 (sk) * 1991-02-01 1998-05-06 Merck Sharp & Dohme Limited Deriváty imidazolu, triazolu a tetrazolu, spôsob i
FR2672602B1 (fr) * 1991-02-12 1993-06-04 Centre Nat Rech Scient Composes derives des beta-carbolines ligands du recepteur des benzodiazepines ayant un effet agoniste inverse et antagoniste vis-a-vis des benzodiazepines et medicaments les contenant.
US5229401A (en) * 1991-09-23 1993-07-20 Hoechst-Roussel Pharmaceuticals Incorporated Substituted pyridinylamino benzo[b]thiophene compounds
US5187159A (en) * 1991-10-07 1993-02-16 Merck & Co., Inc. Angiotensin II antagonists incorporating a substituted 1,3-benzodioxole or 1,3-benzodithiole
GB9210400D0 (en) * 1992-05-15 1992-07-01 Merck Sharp & Dohme Therapeutic agents
US5378846A (en) * 1993-06-11 1995-01-03 Russian-American Institute For New Drug Development 1,2,3,4-tetrahydropyrrolo-[1,2-a]-pyrazine derivatives

Also Published As

Publication number Publication date
NO309652B1 (no) 2001-03-05
IL107386A (en) 1999-03-12
IL107386A0 (en) 1994-01-25
GR3036579T3 (en) 2001-12-31
JP2788551B2 (ja) 1998-08-20
EP0666858A1 (en) 1995-08-16
EP0666858B1 (en) 2001-06-13
CN1051313C (zh) 2000-04-12
DE69330351D1 (de) 2001-07-19
WO1994010171A1 (en) 1994-05-11
PL308669A1 (en) 1995-08-21
RU2134266C1 (ru) 1999-08-10
MY109696A (en) 1997-04-30
CA2148380C (en) 2001-08-14
HUT66011A (en) 1994-08-29
EP1094064A1 (en) 2001-04-25
KR0163371B1 (ko) 1998-12-01
ZA938137B (en) 1995-05-02
FI934825L (fi) 1994-05-03
CZ283001B6 (cs) 1997-12-17
CA2148380A1 (en) 1994-05-11
BR9307348A (pt) 1999-05-11
JPH07508759A (ja) 1995-09-28
FI20002505A7 (fi) 2000-11-15
RU95109927A (ru) 1997-01-10
DE69330351T2 (de) 2001-09-20
CA2340999A1 (en) 1994-05-11
AU5329494A (en) 1994-05-24
FI111257B (fi) 2003-06-30
ATE202102T1 (de) 2001-06-15
PT666858E (pt) 2001-09-28
KR950704313A (ko) 1995-11-17
PL176091B1 (pl) 1999-04-30
HU222235B1 (hu) 2003-05-28
CN1094727A (zh) 1994-11-09
US5886008A (en) 1999-03-23
ES2157224T3 (es) 2001-08-16
EG20396A (en) 1999-02-28
NO951633L (no) 1995-04-28
TW251284B (oth) 1995-07-11
DK0666858T3 (da) 2001-08-27
NZ257059A (en) 1997-07-27
NO951633D0 (no) 1995-04-28
FI20002505L (fi) 2000-11-15
CZ110895A3 (en) 1995-11-15
FI934825A0 (fi) 1993-11-01
AU685066B2 (en) 1998-01-15

Similar Documents

Publication Publication Date Title
CA2340999C (en) 5-arylindole derivatives
AU671959B2 (en) Indole derivatives
CA2349330C (en) Nitrogen containing heterobicycles as factor xa inhibitors
CA2169179C (en) 5-arylindole derivatives
CA2645731A1 (en) N-substituted-azacyclylamines as histamine-3 antagonists
JPH07506825A (ja) ５−ｈｔ１レセプターアゴニストとしての縮合イミダゾール及びトリアゾール誘導体
CA1337202C (en) Cyclic amides which are leukotriene antagonists
US5859261A (en) Synthesis of indolylmaleimides
AU675641B2 (en) Imidazole, triazole and tetrazole derivatives
US5902819A (en) Triazole derivatives

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed